Efficacy and safety of thromboprophylaxis with low-molecular-weight heparin or rivaroxaban in hip and knee replacement surgery
| Autor: | Albrecht Hartmann, Sebastian Werth, Jörg Lützner, Jan Beyer-Westendorf, Thoralf Stange, Lars Donath, Oliver C. Radke, Luise Tittl, Holger Knoth, Eberhard Kuhlisch, Klaus-Peter Günther, Norbert Weiss |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Male
Time Factors Arthroplasty Replacement Hip medicine.medical_treatment Knee replacement Kaplan-Meier Estimate 030204 cardiovascular system & hematology 0302 clinical medicine Rivaroxaban Risk Factors Germany Odds Ratio Registries Arthroplasty Replacement Knee Aged 80 and over Venous Thrombosis Hematology Heparin Middle Aged Treatment Outcome Anesthesia Female medicine.drug medicine.medical_specialty medicine.drug_class Morpholines Low molecular weight heparin Hemorrhage Thiophenes Vte prophylaxis 03 medical and health sciences Fibrinolytic Agents Thromboembolism medicine Humans Blood Transfusion In patient Aged Proportional Hazards Models Retrospective Studies business.industry Anticoagulants Retrospective cohort study Heparin Low-Molecular-Weight Length of Stay Surgery Logistic Models 030228 respiratory system Multivariate Analysis business Hospital stay |
| Zdroj: | Thrombosis and Haemostasis. 109:154-163 |
| ISSN: | 2567-689X 0340-6245 |
| DOI: | 10.1160/th12-07-0510 |
| Popis: | SummaryProspective trials have shown that rivaroxaban thromboprophylaxis is superior over low-molecular-weight heparin (LMWH) in patients undergoing hip and knee replacement surgery. However, patients treated under trial conditions are different from unselected routine patients, which may affect efficacy and safety of thromboprophylaxis. The objective was to evaluate the efficacy and safety of rivaroxaban or LMWH thromboprophylaxis in unselected patients undergoing hip and knee replacement surgery in daily care. In a monocentric, retrospective cohort study in 5,061 consecutive patients undergoing hip and knee replacement surgery a comparison of LMWH (hospital standard in 2006–2007) and rivaroxaban (since 2009) was made with regard to rates of symptomatic VTE, bleeding and surgical complications and length of hospital stay. Rates of symptomatic VTE were 4.1 % (LMWH) and 2.1 % (rivaroxaban; p=0.005) with rates for distal DVT 2.5 vs. 1.1 % (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|